$IDRA Recent News Pfizer, Affymetrix weigh on drug stocks

New Post Public Reply Private Reply Replies (0) Message Board

Dec 11, 2013 at 1:38 PM

$IDRA Recent News

Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Idera tumbles 14% on drug setback 1:52 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 4:37 p.m. Jan. 19, 2010 - MarketWatch
Incyte, Idera move on Novartis deals 2:02 p.m. Nov. 25, 2009 - Val Brickates Kennedy
Novartis terminates pact with Idera 8:28 a.m. Nov. 25, 2009 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:29 p.m. Dec. 26, 2007 - MarketWatch
Idera Pharmaceuticals' president, Karr, resigns 9:08 a.m. Dec. 26, 2007 - Robert Daniel
Idera Pharma President Karr resigns, stays on board 9:03 a.m. Dec. 26, 2007 - Robert Daniel
Idera signs agonist licensing, collaboration with Merck KGaA 7:10 a.m. Dec. 19, 2007 - Sarah Turner
Idera to get up to $381 mln in milestones 7:03 a.m. Dec. 19, 2007 - Steve Goldstein
Idera, Merck KGaA agree collaboration deal 7:02 a.m. Dec. 19, 2007 - Steve Goldstein
Wednesday's biggest stock gainers and decliners 6:03 p.m. Feb. 28, 2007 - Michael Baron
Idera Pharma started at buy at Merriman Curhan Ford 8:54 a.m. Feb. 7, 2007 - Tomi Kilgore
Drug stocks slip; Nuvelo, Neopharm shares plunge on trial results 4:37 p.m. Dec. 11, 2006 - Carolyn Pritchard

9 Biotechnology Stocks to Buy Now 6:00 a.m. Today - InvestorPlace.com
10-Q: IDERA PHARMACEUTICALS, INC. 7:02 a.m. Nov. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Biotech-Focused Baker Bros. Accumulates These 3 Stocks 8:55 a.m. Oct. 1, 2013 - Seeking Alpha
Idera Phase 2 Data Provides For Exciting Q4 2013 And Q1 2014 8:02 a.m. Sept. 25, 2013 - Seeking Alpha
Analysts: Blackstone Mortgage Gaining Traction and 3 Other Research Notes to Browse 1:37 p.m. Aug. 29, 2013 - Wall St. Cheat Sheet
Idera Enters Agreement with NCI to Evaluate Use of TLR Antagonists for Treatment of Genetically Defined Lymphomas 6:39 a.m. Aug. 29, 2013 - benzinga.com
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 6:05 a.m. July 18, 2013 - benzinga.com
Idera Pharma to Issue Positive Phase I Trial Results on TLR Antagonist IMO-8400 5:31 a.m. June 21, 2013 - benzinga.com
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 6:07 a.m. June 5, 2013 - benzinga.com
10-Q: IDERA PHARMACEUTICALS, INC. 6:49 a.m. May 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
Idera Pharmaceuticals Announces Closing of Common Share Offering 2:19 p.m. May 7, 2013 - benzinga.com
Idera Pharmaceuticals Prices 17.5M Share Offering at $0.50/Share 3:59 a.m. May 2, 2013 - benzinga.com
1 Stock to Buy, 1 Stock to Short: Penny Stocks 8:52 a.m. April 16, 2013 - InvestorPlace.com
Idera Phase 2 of IMO-8400 Receives Clearance from Netherlands Competent Group 6:18 a.m. April 1, 2013 - benzinga.com
10-K: IDERA PHARMACEUTICALS, INC. 6:28 a.m. March 11, 2013 - Edgar Online - (EDG = 10Q, 10K)
UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data 11:49 a.m. Jan. 3, 2013 - benzinga.com
3 Biotech Stocks To Consider In The Wake Of Recent Developments 1:51 p.m. Dec. 19, 2012 - Seeking Alpha
4 Reasons Why Merck Could Be The Perfect Stock For Dividend Investors 12:11 p.m. Nov. 30, 2012 - Seeking Alpha
Medical Advances May Help Improve Psoriasis Outcomes 5:18 a.m. Nov. 11, 2012 - Seeking Alpha
Amgen Psoriasis Candidate Impresses - Analyst Blog 4:51 p.m. April 4, 2012 - Zacks.com

Senior Appointments, Stock Splits, New Guidelines, Positive Results, and Clinical Trial Updates - Research Report on Receptos, MEDNAX, CombiMatrix, Anacor, and Idera 8:00 a.m. Dec. 10, 2013 - PR Newswire
Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenstrom's Macroglobulinemia 7:30 a.m. Dec. 4, 2013 - BusinessWire
Idera Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:02 p.m. Nov. 25, 2013 - BusinessWire
Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update 7:45 a.m. Nov. 14, 2013 - BusinessWire
Idera Pharmaceuticals to Host Conference Call to Report Third Quarter 2013 Financial Results on Thursday, November 14, 2013 4:10 p.m. Nov. 7, 2013 - BusinessWire
Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants 3:14 p.m. Sept. 30, 2013 - BusinessWire
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants 8:09 a.m. Sept. 25, 2013 - BusinessWire
Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants 3:01 p.m. Sept. 24, 2013 - BusinessWire
Five Star Equities Issues New Research Reports on EZCH, IDRA, PSTI and UNFI 8:01 a.m. Sept. 13, 2013 - ACCESSWIRE
Idera to Provide Update on Programs at Stifel Nicolaus Healthcare Conference 11:00 a.m. Sept. 12, 2013 - BusinessWire
Idera to Present at the Stifel Nicolaus 2013 Healthcare Conference 8:25 a.m. Sept. 10, 2013 - BusinessWire
Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas 7:30 a.m. Aug. 29, 2013 - BusinessWire
Idera Pharmaceuticals Reports Second Quarter 2013 Financial Results and Corporate Highlights 7:00 a.m. Aug. 15, 2013 - BusinessWire
Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial 7:00 a.m. July 18, 2013 - BusinessWire
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors 8:00 a.m. July 10, 2013 - BusinessWire
Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases 7:00 a.m. July 1, 2013 - BusinessWire
Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013 6:30 a.m. June 21, 2013 - BusinessWire
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis 7:00 a.m. June 5, 2013 - BusinessWire
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results 7:15 a.m. May 15, 2013 - BusinessWire
Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis 6:15 a.m. May 8, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...